Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Progression-Free-Survival
研究概览
简要总结
This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥18 years of age.
- •Provision of fully informed consent prior to any study specific procedures.
- •Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
- •Genetic variants of tumor tissue detected by NGS.
排除标准
- 未提供
结局指标
主要结局
Progression-Free-Survival
时间窗: Assessed up to around 4.5 years
From the time the first patient included in the observational analysis received treatment until disease progression, death due to various causes or censored at the date of last contact
Overall Survival
时间窗: Assessed up to around 4.5 years
From the time the first patient included in the observational analysis received treatment until death due to various causes or censored at the date of last contact
次要结局
- ORR(Assessed up to around 4.5 years)
- Clinical relevance between genomic profiling and overall survival(Assessed up to around 4.5 years)
- Clinical relevance between genomic profiling and progression-free-survival(Assessed up to around 4.5 years)
研究者
Yongchang Zhang
Professor, Deputy Director of Thoracic Oncology Department
Hunan Province Tumor Hospital